Design and Use of a Low Cost, Automated Morbidostat for Adaptive Evolution of Bacteria Under Antibiotic Drug Selection
September 27th, 2016
9.6K views
We describe a low cost, configurable morbidostat that enables the characterization of antibiotic drug resistance by dynamically adjusting the drug concentration. The device can be integrated with a multiplexed microfluidic platform. The approach can be scaled up for laboratory antibiotic drug resistance studies.
Overview
This article presents a low-cost, configurable morbidostat designed to study antibiotic drug resistance by dynamically adjusting drug concentrations. The device can be integrated with a multiplexed microfluidic platform, allowing for scalable laboratory studies.
Key Study Components
Area of Science
- Microbiology
- Antibiotic resistance
- Device engineering
Background
- Antibiotic resistance is a significant public health challenge.
- Understanding the evolutionary pathways of resistance can inform treatment strategies.
- Current methods for studying resistance can be costly and complex.
- A morbidostat offers a novel approach to continuously monitor bacterial growth.
Purpose of Study
- To characterize the evolutionary pathway of antibiotic resistance.
- To demonstrate a low-cost method for antibiotic resistance studies.
- To provide a reconfigurable platform for various experimental needs.
Methods Used
- Assembly of the morbidostat using inexpensive electronic components.
- Continuous monitoring of bacterial growth.
- Dynamically adjusting antibiotic concentrations based on resistance development.
- Utilizing PDMS for creating components of the device.
Main Results
- The morbidostat effectively tracks bacterial growth in real-time.
- Dynamic adjustment of antibiotic concentration is feasible and effective.
- The device can be easily reconfigured for different experiments.
- Low-cost components make this approach accessible for various laboratories.
Conclusions
- The morbidostat is a valuable tool for studying antibiotic resistance.
- This method can enhance understanding of bacterial adaptation.
- Future studies can leverage this platform for broader applications in microbiology.
Frequently Asked Questions
What is a morbidostat?
A morbidostat is a device that continuously monitors bacterial growth and adjusts antibiotic concentrations dynamically.
How does the morbidostat help in studying antibiotic resistance?
It allows researchers to observe how bacteria adapt to antibiotics over time by adjusting drug levels in real-time.
What are the main components of the morbidostat?
The morbidostat is made from low-cost electronic components and includes a culture vial with tubing for drug delivery.
Can the morbidostat be used for other experiments?
Yes, it can be reconfigured for various experimental setups beyond antibiotic resistance studies.
Who conducted this research?
The research was conducted by Po Cheng Liu and Yi Tai Lee, graduate students in the laboratory.
What is the significance of using low-cost components?
Using low-cost components makes the morbidostat accessible to more laboratories, facilitating wider research on antibiotic resistance.
Executive Industry Relevance
Automated morbidostat platforms enable continuous, real-time interrogation of bacterial adaptation under antibiotic pressure, directly supporting predictive confidence in resistance pathway mapping. This capability is critical for early discovery teams seeking to de-risk antibacterial target selection and inform translational strategies for next-generation therapeutics. The low-cost, reconfigurable design facilitates broad adoption across R&D portfolios, accelerating resistance mechanism elucidation and adaptive evolution studies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables dynamic, quantitative assessment of resistance acquisition under controlled drug selection.
- Supports mechanistic de-risking by mapping mutational trajectories in real time.
- Facilitates functional validation of antibacterial targets through adaptive evolution experiments.
- Provides actionable data for portfolio triage and prioritization of resistance-breaking strategies.
Screening & Assay Development
- Delivers standardized, reproducible bacterial culture conditions for downstream susceptibility testing.
- Generates quantitative optical density and IC50 measurements for robust assay development.
- Supports integration with microfluidic platforms for high-content phenotypic screening.
- Enables scalable, multiplexed evaluation of compound efficacy against evolving bacterial populations.
Translational & Preclinical Research
- Aligns laboratory evolution outputs with clinically relevant resistance phenotypes.
- Provides continuity from discovery-stage resistance mapping to preclinical validation of candidate interventions.
- Enables risk-adjusted advancement decisions based on real-world resistance emergence data.
- Supports translational biomarker identification through longitudinal sampling and sequencing.
Pipeline & Workflow Integration
This automated morbidostat platform bridges early discovery, screening, and translational research by enabling continuous adaptive evolution studies and quantitative resistance profiling.
- Discovery Biology: Supports hypothesis-driven interrogation of resistance mechanisms and pathway clarification.
- Screening: Provides reproducible, quantitative outputs for assay standardization and compound evaluation.
- Analytics: Delivers real-time optical density and IC50 data for comparative analysis of resistance dynamics.
- Translational Research: Facilitates alignment of laboratory findings with clinical resistance trends and biomarker development.
- Enterprise Reuse: Offers a modular, reconfigurable platform adaptable to diverse bacterial culture and evolution experiments.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in resistance pathway mapping and target validation.
- Operational Value: Enhances standardization, reproducibility, and scalability of adaptive evolution workflows.
- Strategic Value: Informs go/no-go decisions and reduces late-stage biological risk in antibacterial portfolios.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of resistance-breaking candidates.
Implementation Considerations
- Requires expertise in bacterial culture, device assembly, and adaptive evolution protocols.
- Needs access to basic electronic components, microfluidic integration, and optical density measurement infrastructure.
- Demands cross-team standardization for data comparability and workflow integration.
- Adaptable across bacterial strains and experimental designs with minimal reconfiguration.
- Biohazard containment and biosafety compliance are essential for handling drug-resistant organisms.
Biopharma FAQs
Why does null hypothesis testing matter for resistance pathway mapping?
Null hypothesis testing enables teams to rigorously determine whether observed resistance acquisition is statistically significant under defined drug selection, supporting robust target validation and mechanistic de-risking in antibacterial discovery.
How does independent variable isolation fit adaptive evolution workflows?
Isolating antibiotic concentration as the independent variable allows precise control over selection pressure, enabling clear attribution of resistance phenotypes to specific drug exposures and supporting reproducible adaptive evolution studies.
What do quantitative optical density and IC50 measurements enable?
Quantitative optical density and IC50 outputs provide objective, reproducible metrics for tracking bacterial growth and resistance shifts, facilitating cross-condition comparisons and informing compound efficacy assessments.
Why are replication requirements critical for cross-functional collaboration?
Replication ensures that resistance acquisition and phenotypic changes are consistent and reproducible, enabling reliable data sharing and decision-making across discovery, screening, and translational teams.
What statistical analysis capabilities are required before implementation?
Teams must be equipped to analyze longitudinal growth, resistance, and mutation data using appropriate statistical methods to validate adaptive evolution outcomes and support portfolio advancement decisions.
